?133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling

Hamish Campbell (1) , Nicholas Fleming (2) , Imogen Roth (2) , Sunali Mehta (2, 3) , Anna Wiles (2, 3) , Gail Williams (2) , Claire Vennin (4, 5) , Nikola Arsic (6) , Ashleigh Parkin (4, 5) , Marina Pajic (7, 4, 5) , Fran Munro (2) , Les Mcnoe (2) , Michael Black (2) , John Mccall (2) , Tania L. Slatter (2) , Paul Timpson (4, 5) , Roger Reddel (1) , Pierre Roux , Cristin Print (3, 8) , Margaret A. Baird (2, 3) , Antony W. Braithwaite (1, 2, 3)

1 Children's Medical Research Institute [Westmead, Australia]
2 University of Otago [Dunedin, Nouvelle-Zélande]
3 Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
4 Garvan Institute of medical research
5 St. Vincent’s Clinical School, Faculty of Medicine
6 CRBM - Centre de recherche en Biologie cellulaire de Montpellier
7 The Kinghorn Cancer Centre - Cancer Division [Sydney, Australia]
8 School of Chemical Sciences [Auckland]

Domaines: Biologie cellulaire

Hamish Campbell, Nicholas Fleming, Imogen Roth, Sunali Mehta, Anna Wiles, et al.. ?133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling. Nature Communications, 2018, 9 (1), ⟨10.1038/s41467-017-02408-0⟩. ⟨hal-01872976⟩